Poseida Therapeutics’ (PSTX) “Neutral” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Poseida Therapeutics (NASDAQ:PSTX) in a report issued on Tuesday morning, Marketbeat.com reports. They currently have a $9.00 target price on the stock, down from their prior target price of $20.00.

Poseida Therapeutics Price Performance

Shares of PSTX opened at $9.31 on Tuesday. Poseida Therapeutics has a 52-week low of $1.87 and a 52-week high of $9.42. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.20 and a current ratio of 3.20. The business’s 50 day moving average price is $3.25 and its two-hundred day moving average price is $3.10. The firm has a market cap of $907.35 million, a PE ratio of -14.78 and a beta of 0.54.

Insider Buying and Selling at Poseida Therapeutics

In other Poseida Therapeutics news, Chairman Mark J. Gergen sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $9.27, for a total value of $278,100.00. Following the transaction, the chairman now directly owns 651,291 shares of the company’s stock, valued at approximately $6,037,467.57. The trade was a 4.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Poseida Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company increased its holdings in shares of Poseida Therapeutics by 14.2% during the second quarter. The Manufacturers Life Insurance Company now owns 28,520 shares of the company’s stock valued at $83,000 after acquiring an additional 3,552 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Poseida Therapeutics by 4.2% during the second quarter. Rhumbline Advisers now owns 97,012 shares of the company’s stock valued at $283,000 after acquiring an additional 3,875 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of Poseida Therapeutics by 5.9% during the second quarter. American Century Companies Inc. now owns 90,487 shares of the company’s stock valued at $264,000 after acquiring an additional 5,023 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Poseida Therapeutics by 1.6% during the second quarter. Dimensional Fund Advisors LP now owns 599,812 shares of the company’s stock valued at $1,749,000 after acquiring an additional 9,672 shares in the last quarter. Finally, Bayesian Capital Management LP bought a new stake in shares of Poseida Therapeutics during the first quarter valued at approximately $33,000. 46.87% of the stock is owned by institutional investors and hedge funds.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.